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The cytokine gamma interferon (IFN-␥) and the calcitropic steroid hormone 1,25-dihydroxyvitamin D
(1,25D) are activators of macrophage immune function. In sarcoidosis, tuberculosis, and several granulomatoses, IFN-␥ induces 1,25D synthesis by macrophages and inhibits 1,25D induction of 24-hydroxylase, a key
enzyme in 1,25D inactivation, causing high levels of 1,25D in serum and hypercalcemia. This study delineates
IFN-␥–1,25D cross talk in human monocytes-macrophages. Nuclear accumulation of Stat1 and vitamin D
receptor (VDR) by IFN-␥ and 1,25D promotes protein-protein interactions between Stat1 and the DNA binding
domain of the VDR. This prevents VDR-retinoid X receptor (RXR) binding to the vitamin D-responsive
element, thus diverting the VDR from its normal genomic target on the 24-hydroxylase promoter and antagonizing 1,25D–VDR transactivation of this gene. In contrast, 1,25D enhances IFN-␥ action. Stat1-VDR interactions, by preventing Stat1 deactivation by tyrosine dephosphorylation, cooperate with IFN-␥/Stat1-induced
transcription. This novel 1,25D–IFN-␥ cross talk explains the pathogenesis of abnormal 1,25D homeostasis in
granulomatous processes and provides new insights into 1,25D immunomodulatory properties.
activated vitamin D receptor (VDR) as a transcription factor
(6, 12). 1,25D binding to the VDR induces a conformational
change in the VDR molecule that activates the VDR to translocate to the nucleus and heterodimerize with the retinoid X
receptor (RXR). The VDR-RXR complex then binds to specific DNA sequences, known as vitamin D-responsive elements
(VDREs), in the 24-hydroxylase promoter (11) and recruits
nuclear receptor coactivator molecules to induce transcription
(8). Studies of the human monocytic cell line THP-1 demonstrated that IFN-␥ may directly impair 1,25D induction of
24-hydroxylase gene transcription (16). IFN-␥ inhibited 1,25D
induction of 24-hydroxylase mRNA, an effect that did not
result from defective binding of 1,25D to VDR or reduced
stability of the 24-hydroxylase mRNA, suggesting the existence
of interactions between the very distinct signaling pathways of
IFN-␥ and 1,25D.
In the case of IFN-␥, most responses to the cytokine involve
the activation of the latent cytosolic protein Stat1 (15, 45).
IFN-␥ binding to its cell membrane receptor induces rapid
assembly of a complete IFN-␥ receptor complex with Jak1 and
Jak2 enzymes, which phosphorylate one another and then
phosphorylate the receptor. Receptor phosphorylation results
in the formation of Stat1 docking sites. Upon phosphorylation
at tyrosine 701, Stat1 homodimerizes, translocates to the nucleus, and binds DNA at specific IFN-␥ activation sequences
(GAS), where it either activates or represses transcription (23).
Maximal transcriptional activity by active Stat1 homodimers
also requires Stat1 phosphorylation at serine 727 (17, 52) and
recruitment to the transcription initiation complex of the CBPp300 family of coactivators (54).
The present study delineates the mechanism and functional
relevance of the interactions between the distinct signaling
pathways for the steroid hormone 1,25D and the cytokine
IFN-␥. IFN-␥ antagonizes 1,25D-VDR transcriptional activa-

1,25-Dihydroxyvitamin D (1,25D), the hormonal form of
vitamin D, is a potent regulator of calcium homeostasis (8). In
healthy individuals, to maintain calcium concentrations within
the physiological range, 1,25D tightly controls its own levels in
serum (26) by dual mechanisms: suppressing its own synthesis
by renal and extrarenal 1␣-hydroxylase and inducing 24-hydroxylase, the key enzyme in 1,25D metabolic inactivation (27).
In contrast, in sarcoidosis, tuberculosis, several granulomatoses, and rheumatoid arthritis, abnormal 1,25D homeostasis is
the cause of hypercalcemia (1, 18, 19, 34). In these patients,
high levels of 1,25D in serum result from excessive 1,25D
synthesis by the disease-activated macrophage (2, 3, 28) and
loss of the capacity of 1,25D to regulate its own synthesis and
degradation (16, 42). The demonstration of a direct correlation
between pleural levels of gamma interferon (IFN-␥) and 1,25D
(2) suggested the involvement of the cytokine in the abnormalities in 1,25D homeostasis. In fact, exposure of normal monocytes, pulmonary alveolar macrophages, or the monocytic cell
line THP-1 to IFN-␥ markedly enhances macrophage 1,25D
production and antagonizes 1,25D regulation of 1␣- and 24hydroxylases (16). Clearly, in vivo and in vitro, IFN-␥ impairs
1,25D control of its own synthesis and catabolism.
These studies addressed the mechanisms mediating the antagonistic effects of IFN-␥ on 1,25D regulation of its own
homeostasis. Since the mechanism for 1,25D-suppression of
1␣-hydroxylase gene transcription is poorly understood (37),
we focused on the effects of IFN-␥ on 1,25D enhancement of
its own catabolism. 1,25D induction of 24-hydroxylase expression is a typical 1,25D genomic action, mediated by ligand* Corresponding author. Mailing address: Renal Division, Washington University School of Medicine, 660 S. Euclid, St. Louis, MO 63110.
Phone: (314) 362-8243. Fax: (314) 362-8237. E-mail: adusso@im.wustl
.edu.
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tion of 24-hydroxylase. Direct protein-protein interactions between activated Stat1 and the DNA binding domain (DBD) of
the VDR impair VDR-RXR binding to human 24-hydroxylase
VDRE. In contrast, 1,25D enhances IFN-␥ action. Stat1-VDR
interactions prolong Stat1 activation, thus enhancing IFN-␥–
Stat1 transcriptional regulation of IFN-␥-responsive genes.

Plasmids and antibodies. 8⫻GAS-Luc was described previously (9, 22). Human 24-hydroxylase (⫺1262, ⫹99)–chloramphenicol acetyltransferase (CAT)
and monoclonal mouse anti-VDR VG1 were from H. F. DeLuca (University of
Wisconsin–-Madison). pSG5VDR, GST-VDR (4–427), 4⫻ rat osteocalcin
VDRE-Luc, and anti-VDR antibody 9A7 were obtained from Paul MacDonald
(Case Western Reserve University, Cleveland, Ohio). GST-VDR (4–133) and
GST-VDR (89–427) were provided by Mark Haussler (University of Arizona—
Tucson). pET-Stat1 was obtained from Focco Van Decker (Cleveland Clinic).
TGL-IP10 was obtained from Richard Ransohoff (Cleveland Clinic). LMX1B
expression plasmid was obtained from Michael Rauchman (Washington University, St. Louis, Mo.). Anti-N terminus Stat1 and anti-pY701 Stat1 were purchased
from Signal Transduction and New England Biolabs, respectively.
Cell culture. THP-1 cells were grown in suspension in RPMI 1640 containing
10% fetal bovine serum. Differentiated THP-1 cells were induced to acquire a
macrophage phenotype by exposure to 160 nM phorbol 12-myristate 13-acetate
(Sigma, St. Louis, Mo.) for 24 h. 2fTGH, U3A, and reconstituted U3A cells
(from George Stark, Cleveland Clinic) were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. For all cell types,
treatment with 1,25D (a gift from Milan Uskokovick, Hoffman-La Roche, Nutley, N.J.) and IFN-␥ (Endogen) was conducted in serum-free medium containing
1% fatty-acid-free albumin. Incubations were done at 37°C in humidified 95%
air–5% CO2.
Transfection and reporter assays. Cells were transiently transfected by using
Superfect reagent (Qiagen) according to the manufacturer’s specifications. Renilla luciferase or ␤-galactosidase (Promega) was cotransfected as an internal
standard. Firefly and Renilla luciferase, CAT, and ␤-galactosidase activities were
all measured using Promega’s kits.
Immunoprecipitation and immunoblot analysis. THP-1, 2fTGH, or U3A cells
were either untreated or stimulated with IFN-␥ (1,000 IU/ml), 1,25D (50 nM), or
both for 4 h. Cell extracts were prepared as described previously (30). Whole-cell
extracts (600 g or 1 mg) were immunoprecipitated with anti-VDR 9A7 or
nonspecific immunoglobulin G (IgG). The immune complexes were collected on
Staph-A beads (Sigma) coated with goat anti-rat antibody (Pierce) and washed
four times in lysis buffer (200 mM Tris-HCl [pH 7.4], 2 mM EDTA, 0.5%
Nonidet P-40, 0.3 mM sodium orthovanadate, 50 mM sodium fluoride, 0.5 mM
dithiothreitol, and a cocktail of protease inhibitors [Boehringer Mannheim]).
Proteins were resolved on sodium dodecyl sulfate (SDS)–7.5% polyacrylamide
gels, transferred to nitrocellulose membranes, and probed with the anti-Stat1
antibody followed by anti-mouse IgG coupled to horseradish peroxidase (BioRad). The transfers were analyzed by using the Supersignal chemiluminescent
reagent (Pierce).
EMSAs. Nuclear extracts or recombinant proteins were prepared, and electrophoretic mobility shift assays (EMSAs) were performed as described by Chen
and DeLuca (11) or by Kotanides and Reich (29) for VDRE and GAS, respectively. The probes used were double-stranded oligonucleotides containing the
24-hydroxylase promoter-proximal VDRE sequence, 5⬘-ATGGAGTCAGCGA
GGTGAGCGAGGGCGTCC-3⬘ (wild type) and 5⬘-ATGGAGAGTGCGAGG
AGTGCGAGGAAATCC-3⬘ (mutant), or the high-affinity Stat binding site, SIE
(m67), described by Vignais et al. (50).
GST pull-down. The constructs for bacterial expression of glutathione Stransferase (GST) fusion proteins were transformed in Escherichia coli DH5␣
(Gibco-BRL). The proteins were induced and purified as described previously
(13) and bound to glutathione-agarose beads (Sigma). In vitro-transcribed and
-translated Stat1 and luciferase were synthesized and labeled with [35S]methionine (Redivue; Amersham Pharmacia) utilizing T7 TNT Reticulocyte Lysate
Master Mix (Promega) according to the manufacturer’s instructions and incubated with the GST beads. The beads were washed four times with binding buffer
(20 mM Tris-HCl [pH 7.6], 50 mM NaCl, 0.2% Nonidet P-40, 1 mM dithiothreitol, and a cocktail of protease inhibitors [Boehringer Mannheim]) and two times
with 50 mM Tris-HCl (pH 8.0) and eluted in 10 mM reduced glutathione–50 mM
Tris-HCl, pH 8.0. The eluted fraction was resolved by SDS-polyacrylamide gel
electrophoresis and analyzed using a PhosphorImager (Molecular Dynamics).

Immunofluorescence. 2fTGH or U3A cells, seeded on coverslips, were transfected with VDR and either untreated or exposed for 30 min to 1,25D (50 nM)
or IFN-␥ (1,000 IU/ml). The cells were fixed in methanol, blocked for 1 h in 10%
goat serum–1% bovine serum albumin (BSA)–0.02% NaN3 in phosphate-buffered saline, washed once with Tris-buffered saline (TBS), and incubated overnight with anti-VDR VG1 (1:50 dilution in 1% BSA in TBS). The coverslips were
washed three times in TBS, incubated with anti-mouse fluorescein isothiocyanate-conjugated antibody for 1 h in the dark followed by three washes with TBS,
and mounted on slides. Images were obtained from a fluorescent confocal microscope (MRC 1024; Bio-Rad).
RNase protection assays. Total RNA was prepared using the Trizol (Tel-Test)
method according to the manufacturer’s instructions. 32P-labeled riboprobes
(IFN-␥-inducible protein 10 [IP-10] from Pharmingen; glyceraldehyde-3-phosphate dehydrogenase [GAPDH] from Ambion) were generated by in vitro transcription with T7 RNA polymerase (Promega). mRNAs for IP-10 and GAPDH
were measured according to the manufacturer’s instructions for RiboQuant
(Pharmingen). Protected fragments were separated by electrophoresis on a 4.5%
polyacrylamide–urea gel.

RESULTS
IFN-␥ antagonizes 1,25D transcriptional activation of 24hydroxylase. To test whether IFN-␥ antagonism on 1,25D induction of 24-hydroxylase was at the transcriptional level, the
human fibrosarcoma cell line 2fTGH or the Stat1-null, 2fTGH
derived-U3A cells were transfected with a CAT reporter plasmid driven by the human 24-hydroxylase promoter (⫺1262 to
⫹99). A ␤-galactosidase expression plasmid was cotransfected
to normalize for transfection efficiency. In 2fTGH cells, 1,25D
treatment (50 nM 1,25D) strongly induced transcription by this
promoter (Fig. 1A) (11). IFN-␥ (1,000 U/ml) had no effect on
basal transcriptional activity; however, simultaneous treatment
with 1,25D and IFN-␥ reduced the transcriptional response to
1,25D by threefold. In Stat1-null U3A cells, there was no
difference in transcriptional activity between cells treated with
1,25D alone and those exposed to 1,25D plus IFN-␥. These
findings indicate that IFN-␥ impairs 1,25D transcriptional activation of 24-hydroxylase through a Stat1-mediated mechanism.
VDRE is sufficient for IFN-␥ antagonism. A similar set of
experiments was conducted with 2fTGH and U3A cells transiently transfected with a firefly luciferase reporter construct
driven by an artificial promoter containing four copies of rat
osteocalcin VDRE. As shown in Fig. 1B, this artificial promoter recapitulated the transcriptional regulation of the fulllength human 24-hydroxylase promoter in the induction by
1,25D in both 2fTGH and U3A cells. Also, the antagonism on
gene transcription by simultaneous treatment with IFN-␥ and
1,25D persisted in 2fTGH but not U3A cells. This experiment
suggests that the presence of positive consensus DR3 VDREs
in a promoter is sufficient for IFN-␥ antagonism on 1,25DVDR transcriptional activation.
IFN-␥ reduces VDR/RXR binding to VDRE. IFN-␥ treatment inhibited 1,25D induction of 24-hydroxylase gene transcription but did not change the basal activity of the promoter
(Fig. 1A), 1,25D binding to the VDR (16), or nuclear VDR
levels (data not shown). Since IFN-␥ antagonism persisted in a
VDRE-driven artificial promoter (Fig. 1B), the effects of the
cytokine on VDR-RXR binding to VDRE were next tested.
EMSAs were conducted using the proximal VDRE of the
human 24-hydroxylase promoter as a probe and nuclear extracts from THP-1 cells (Fig. 1C). 1,25D treatment induced a
retarded band (compare lanes 2 and 3), which corresponds to
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endogenous VDR-RXR bound to VDRE as judged by (i)
comigration with recombinant VDR-RXR bound to VDRE
(lane 1), (ii) competition by an excess of cold VDRE but not
mutant VDRE (lanes 6 and 7), and (iii) inhibition of binding
by incubation with anti-VDR 9A7 antibody (lane 8). VDR/
RXR binding to VDRE was almost completely abolished by
simultaneous treatment with 1,25D and IFN-␥ (compare lanes
3 and 5). When nuclear extracts from 2fTGH cells were utilized, a similar pattern was found (Fig. 1D, lanes 1 to 4). In
contrast, in Stat1-null U3A cells, there was no difference in
endogenous VDR-RXR binding to VDRE between nuclear
extracts from cells treated with 1,25D and extracts from cells
treated with 1,25D plus IFN-␥ (Fig. 1D, compare lanes 7 and
9). Taken together, these findings demonstrate that IFN-␥

impairs VDR-RXR binding to VDRE through a Stat1-mediated mechanism.
VDR interacts with Stat1. Immunoprecipitation studies examined VDR-Stat1 interactions. VDR-overexpressing 2fTGH
and U3A cells were either untreated or treated with 1,25D,
IFN-␥, or both for 4 h. Stat1 coprecipitated with the VDR
when 2fTGH extracts were immunoprecipitated with antiVDR but not with nonspecific IgG or when extracts from U3A
cells were used (Fig. 2A). These results demonstrate that VDR
and Stat1 interact in vivo. Stat1 coprecipitated with VDR in
every experimental condition tested (lanes 4 to 7), indicating
that VDR and Stat1 interact independently of 1,25D or IFN-␥
activation.
Similar results were obtained when THP-1 cells, expressing
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FIG. 1. IFN-␥ antagonizes 1,25D transcriptional activity. (A) The human 24-hydroxylase promoter (⫺1262, ⫹99) linked to CAT and a
␤-galactosidase expression plasmid were transiently transfected into wild-type 2fTGH or Stat1-null (U3A) cells. CAT activity was measured in cell
lysates from untreated cells (C) or cells treated with 50 nM 1,25D (D), 1,000 U of IFN-␥/ml (␥), or both (␥D) for 16 h. Results represent the means
⫾ standard errors of the means of duplicate measurements from four independent experiments. (B) (VDRE)4-Luc and ␤-galactosidase expression
plasmid were transiently transfected into 2fTGH or U3A cells. Luciferase activity was measured in cell lysates from cells treated as described for
panel A. Results represent the means ⫾ standard errors of the means of triplicate measurements from two independent experiments. (C) EMSA
using the proximal VDRE of the human 24-hydroxylase promoter as a probe and nuclear extracts from THP-1 cells, treated for 4 h as described
for panel A. Recombinant VDR and RXR (lane 1), incubation with a 300 M excess of cold wild-type (lane 6) or mutant (lane 7) VDRE, and
incubation with anti-VDR 9A7 antibody (lane 8) served as controls. (D) EMSA using nuclear extracts from 2fTGH or U3A cells treated as
described for panel C. n.s., nonspecific band.
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endogenous levels of VDR, were used (Fig. 2B). Clearly, IFN␥-mediated Stat1 phosphorylation at tyrosine 701 was not required for Stat1 to interact with the VDR. Consequently, in
vitro-transcribed and -translated Stat1 was tested in GST pulldown assays using different GST-VDR fusion proteins to map
Stat1-VDR interactions in vitro. GST alone did not interact
with Stat1 (Fig. 2C, lane 2). GST fused with full VDR (amino
acids 4 to 427) interacted with Stat1 in a 1,25D-independent
manner (Fig. 2C, lanes 7 and 8). A C-terminal fusion VDR,
comprising amino acids 89 to 427, which contains the ligand
binding domain of the VDR, did not interact with Stat1 (Fig.
2C, lanes 5 and 6). In contrast, an N-terminal fusion VDR,
comprising amino acids 4 to 133, which contains the DBD,
bound Stat1 with an affinity stronger than that of full-length
VDR (lanes 3 and 4). In vitro-transcribed and -translated luciferase did not interact with any of the GST-VDR fusion
proteins. These observations demonstrate direct interactions

between Stat1 and the VDR, since no additional cellular factors were needed. The interaction maps to the DBD of the
VDR, and no posttranslational modifications of Stat1, i.e.,
arginine 31 methylation (36) or serine 727 (52) or tyrosine 701
(43) phosphorylation, are required. The demonstration that
the ligand binding domain of the VDR is not required is
consistent with Stat1-VDR interaction being 1,25D independent.
IFN-␥ treatment drives unliganded VDR into the nucleus.
Because Stat1-VDR interaction was ligand independent, we
analyzed whether IFN-␥ treatment could affect VDR subcellular localization. 2fTGH or U3A cells were transiently transfected with VDR and treated with 1,25D or IFN-␥ for 30 min.
The subcellular localization of the VDR was examined by
indirect immunofluorescence. In both 2fTGH (Fig. 2D1 and
D2) and U3A (data not shown) cells, the VDR was predominantly cytosolic in untreated cells and translocated to the nu-
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FIG. 2. VDR-Stat1 interaction. (A and B) Whole-cell extracts (600 g of total protein) from VDR-transfected 2fTGH and U3A cells (A) or
untransfected THP-1 (1 mg of total protein) (B) cells that were either untreated or treated with 50 nM 1,25D, 1,000 U of IFN-␥/ml, or both for
4 h were immunoprecipitated with anti-VDR 9A7 or nonspecific IgG and analyzed by Western blotting with anti-Stat1. (C) (Top) Schematic
representation of the VDR. (Bottom) GST pull-down assay utilizing different GST-VDR fusion proteins purified from E. coli and bound to
glutathione-agarose beads. Added was 1 M 1,25D (⫹ lanes) or ethanol vehicle (⫺ lanes). 35S-labeled Stat1 and luciferase were synthesized in vitro
and incubated with the beads. After washing and elution, samples were subjected to SDS–10% polyacrylamide gel electrophoresis and autoradiographed. Numbers at right show molecular mass in kilodaltons. (D) Indirect VDR immunofluorescence in 2fTGH or U3A cells transiently
transfected with VDR, either untreated or exposed to 50 nM 1,25D or 1,000 U of IFN-␥/ml for 30 min at 37°C, using a mouse monoclonal antibody
against the VDR and detected with fluorescein isothiocyanate-conjugated anti-mouse antibody.
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cleus within 30 min after 1,25D treatment, in agreement with
previous reports (7). In 2fTGH cells treated with IFN-␥ alone,
a subset of the VDR was present in the nucleus in the absence
of 1,25D stimulation of VDR translocation (Fig. 2D3). IFN-␥
treatment was unable to translocate VDR to the nucleus in
U3A cells (Fig. 2D4). Thus, IFN-␥-activated Stat1 can interact
with and translocate unliganded VDR into the nucleus.
Stat1 abrogates VDR-RXR binding to VDRE. The findings
that IFN-␥ treatment impairs endogenous VDR-RXR binding
to VDRE and that Stat1 and VDR interact in vivo and in vitro
led us to determine whether Stat1 directly influenced VDRRXR DNA binding. To this end, EMSAs were performed
using the proximal VDRE of the human 24-hydroxylase promoter as a probe and recombinant proteins. Whereas VDRRXR binding to VDRE was almost completely abolished in
the presence of recombinant Stat1 (Fig. 3A, compare lanes 1
and 2), BSA, at the same concentration, had no significant
effect (Fig. 3A, lanes 3 and 4).
Since the Stat1-interacting domain of the VDR mapped to
the N-terminal region containing the DBD, the possibility that
Stat1 impaired VDR-DNA binding by blocking the DBD of
the VDR was next tested. Figure 3B shows that the N terminus
of the VDR binds VDRE, presumably as a monomer in the
3⬘-half site (24, 25). Stat1 inhibited the binding to DNA of this
recombinant protein in a dose-dependent fashion (Fig. 3B,

lanes 1 to 4). The effect was Stat1 specific, since BSA (Fig. 3B,
lanes 4 to 8), tested at identical concentrations, had no effect.
These results indicate that IFN-␥, by activating Stat1 and inducing its nuclear translocation, promotes Stat1 interaction
with the DBD of the VDR, which blocks VDR-RXR binding
to 24-hydroxylase VDRE, therefore inhibiting 1,25D induction
of 24-hydroxylase gene transcription. These findings could also
explain the slight but significant increase in 1,25D-induced
transcription in U3A cells over that in 2fTGH cells (Fig. 1A
and B). Possibly, in 2fTGH cells, small amounts of inactive
Stat1 in the nucleus bind VDR-DBD, slightly decreasing
1,25D-mediated transcription, an inhibition that cannot occur
in U3A cells.
1,25D has a synergistic effect on IFN-␥-mediated transcription. Given that Stat1-VDR interactions impaired VDR-mediated transcription, their impact on Stat1-mediated transcription was tested. 2fTGH and U3A cells were transiently
transfected with a firefly luciferase reporter construct driven by
a VDRE-less promoter containing eight copies of GAS. Cotransfection of a cytomegalovirus-Renilla luciferase reporter
was used to assess transfection efficiency. In 2fTGH cells,
IFN-␥ treatment strongly induced transcription (Fig. 4A). As
expected, U3A cells did not respond to IFN-␥. 1,25D, which
had no effect on basal transcriptional activity by itself, enhanced IFN-␥-induced transcription. Furthermore, VDR over-
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FIG. 3. Stat1 abrogates VDR binding to VDRE. (A) EMSA using the proximal VDRE of the human 24-hydroxylase promoter as a probe and
recombinant VDR and RXR (0.1 g each) with or without recombinant Stat1 or BSA (1 g each). Every reaction mixture contained 1 M 1,25D.
(B) EMSA performed as described for panel A using the N-terminal (amino acids 4 to 133) portion of the VDR (0.1 g). Binding reaction mixtures
included the indicated amounts (micrograms) of Stat1 or BSA.
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expression in 2fTGH cells increased the transcription by this
GAS-driven promoter, whereas the unrelated developmental
transcription factor LMX1B had no effect (Fig. 4C).
To further characterize domains and posttranslational modifications of the Stat1 molecule necessary for 1,25D–IFN-␥
synergism, experiments were conducted with U3A cells stably
transfected to rescue the expression of wild-type Stat1 (p91) or
different Stat1 mutants (Fig. 4B). Transcriptional synergy was
rescued in U3A cells reconstituted with wild-type Stat1 (p91)
but not with either a C-terminal deletion mutant lacking 7 kDa
in the transactivation domain (p84) or a tyrosine phosphorylation mutant, Y701F. These results indicate that both tyrosine
phosphorylation and the presence of a functional Stat1 transactivation domain are required for the synergy.
VDR prolongs Stat1 activation. Nuclear Stat1 dephosphorylation by a yet-unknown phosphatase is one of the mechanisms by which the IFN-␥ response is reduced (20, 21). The
tyrosine phosphorylation of Stat1 reaches a maximum between
30 min and 1 h of IFN-␥ treatment, and it starts to decrease by
2 h (38, 43). To gain some insight into potential mechanisms
mediating VDR enhancement of Stat1-mediated transcription,
EMSAs were conducted with a consensus GAS as probe and
nuclear extracts from 2fTGH cells treated with 1,25D, IFN-␥,
or both for 4 h. Simultaneous treatment with 1,25D increased
Stat1 DNA binding (Fig. 5A, lanes 3 and 4). VDR overexpression further increased Stat1 binding to GAS (lanes 7 and 8).
Western blot analysis showed that 1,25D treatment and/or
VDR overexpression resulted in increased levels of tyrosinephosphorylated Stat1, with no changes in total Stat1 (Fig. 5B).
Time course experiments showed that simultaneous treatment
with IFN-␥ and 1,25D prolonged Stat1 DNA binding compared to that of IFN-␥ treatment alone (Fig. 5C). These findings suggest that 1,25D-VDR could enhance IFN-␥ transcriptional activity by prolonging the activated state of Stat1.
1,25D synergizes with IFN-␥ in the induction of IP-10.
1,25D-VDR synergism on IFN-␥ transcriptional activity was
next tested in an endogenous gene, that for IP-10, a potent
chemokine (33). RNase protection assays measured IP-10
steady-state mRNA levels in differentiated THP-1 cells (macrophage phenotype) and in peripheral blood monocytes from
four healthy volunteers. In both THP-1 cells and normal
monocytes, the induction of IP-10 by IFN-␥ was further enhanced by simultaneous treatment with the cytokine and 1,25D
(Fig. 6A, left and right panels, respectively). Densitometric
quantitation of IP-10/GAPDH mRNA ratios showed that simultaneous treatment with 1,25D and IFN-␥ increased by 60%
the induction of IP-10 mRNA by IFN-␥ alone (Fig. 6B). ⌻ransient-transfection studies of 2fTGH cells with a luciferase reporter construct driven by the human IP-10 promoter recapitulated the regulation found in mRNA levels (Fig. 6C). This
synergy in the induction of IP-10 indicates that the effects
observed in a GAS-driven artificial promoter take place, indeed, in an endogenous promoter.
DISCUSSION
The present study, designed to characterize the mechanisms
mediating IFN-␥ antagonism on 1,25D control of its own homeostasis, demonstrates a novel cross talk between the distinct
signaling pathways of the cytokine IFN-␥ and the hormonal
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FIG. 4. 1,25D synergy on IFN-␥-mediated transcription. (A) Cooperative effects of 1,25D on Stat1-induced transcription. (B) Requirements of the Stat1 molecule in 1,25D–IFN-␥ synergy. (C) VDR overexpression enhances Stat1-mediated transcription. 2fTGH cells, U3A
cells, and U3A cells reconstituted with different Stat1 mutants were
transiently transfected with a luciferase reporter construct driven by
eight copies of the consensus GAS (TTCTCGGAA) and 0.1 g of
either human VDR expression vector, human LMX1B expression vector, or vector alone when indicated. Twenty-four hours after transfection, cells were either untreated (C) or exposed to 10 nM 1,25D (D),
1,000 IU of IFN-␥/ml (␥), or both (␥D) as indicated for 4 h. Luciferase
activity was determined in cell lysates. Bars and error bars represent
means ⫾ standard errors of the means from triplicate measurements
from two (C) or three (A and B) independent experiments.
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form of vitamin D. Direct protein-protein interactions between
Stat1 and the VDR, the transcription factors for IFN-␥ and
1,25D, inhibit 1,25D transcriptional activity and enhance Stat1mediated transcription.
In vitro studies using recombinant proteins addressed the
mechanisms for IFN-␥ inhibition of 1,25D transcriptional activity, demonstrating that (i) Stat1-VDR interactions also occur in the absence of ligand-mediated activation of either pro-

tein, (ii) Stat1 binds the DBD of the VDR, and (iii) Stat1
binding to the DBD of the VDR is sufficient to reduce VDR
binding to VDRE. The biological relevance of these findings
was confirmed in vivo. Coimmunoprecipitation experiments
with THP-1 and 2fTGH cells showed that endogenous nuclear
Stat1 and the VDR physically interact. In both cell types, Stat1
binds the VDR, reducing VDR-RXR binding to the 24-hydroxylase VDRE. In 2fTGH cells, IFN-␥-induced reduction in
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FIG. 5. VDR prolongs Stat1 activation. (A) EMSA using a consensus GAS as a probe and nuclear extracts from untransfected 2fTGH cells or
from cells transiently transfected with human VDR expression vector. Cells were either untreated or treated for 4 h with 50 nM 1,25D, 1,000 U
of IFN-␥/ml, or both. The right panel shows supershift analysis utilizing anti-VDR or anti-Stat1 antibodies. (B) Western blots from cell extracts
treated as described for panel A, probed with anti-pY701 Stat1, anti-Stat1, and anti-VDR. (C) EMSA analysis was done as described for panel
A with cell extracts from untransfected 2fTGH cells that were treated with 1,000 U of IFN-␥/ml or 1,000 U of IFN-␥/ml plus 50 nM 1,25D for the
indicated periods of time.
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VDR/RXR binding to VDRE resulted in decreased 1,25DVDR transcriptional activation of the 24-hydroxylase gene. In
Stat1-null U3A cells, neither VDR-RXR binding to VDRE
nor 1,25D transactivation of 24-hydroxylase was impaired by
IFN-␥ treatment. Since both proximal and distal VDREs in the

human 24-hydroxylase promoter are typical VDRE sequences,
inhibitory effects of IFN-␥ identical to those exerted on 1,25D
transactivation of human 24-hydroxylase could affect other
genes induced by 1,25D through classical VDREs. In fact,
IFN-␥ antagonized 1,25D induction of a rat osteocalcin
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FIG. 6. 1,25D synergy on IFN-␥ induction of the IP-10 gene. (A) Normal blood monocytes were left untreated or treated with 50 nM 1,25D,
150 U of IFN-␥/ml, or both for 18 h. IP-10 and GAPDH mRNAs were measured by RNase protection assays. (B) Relative IP-10/GAPDH mRNA
levels in peripheral blood monocytes from four healthy volunteers (left graph) or differentiated THP-1 cells (right graph) from two independent
experiments. Results represent the means ⫾ standard errors of the means. (C) 2fTGH cells were transiently transfected with TGL-IP10.
Twenty-four hours after transfection, cells were either untreated (C) or exposed to 10 nM 1,25D (D), 500 IU of IFN-␥/ml (␥), or both (␥D) as
indicated for 24 h. Luciferase activity was determined in cell lysates. Bars and error bars represent means ⫾ standard errors of the means from
triplicate measurements.
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VDRE-driven reporter (Fig. 1B). Thus, the mechanisms described by these studies may explain IFN-␥ antagonism on
1,25D induction of the osteocalcin gene (39) and IFN-␥ reduction of bone formation (44).
In contrast to the inhibitory effects of Stat1-VDR interactions on 1,25D action, 1,25D has cooperative effects on IFN-␥
47–Stat1 transcriptional activation. Specifically, 1,25D enhanced IFN-␥ induction of the mRNA levels of the potent
chemokine IP-10 in normal human monocytes and in differentiated THP-1 cells (macrophage phenotype), as well as IFN-␥
transactivation of a human IP-10 promoter-driven reporter.
1,25D synergy on Stat1-induced transcription was reproduced
in 2fTGH cells in a GAS-driven, VDRE-less artificial promoter. VDR-Stat1 synergy increased with VDR cotransfection.
Cross talk between Stat proteins and steroid receptors has
been reported. Similar to the functional interactions between
Stat1 and the VDR, Stat5 antagonizes transactivation of glu-

cocorticoid receptor (GR)-responsive promoters through direct protein-protein interactions that also result in GR synergism on Stat5-mediated transcription of the ␤-casein gene (47).
Further characterization of GR-Stat5 interactions revealed the
DBD of the GR as dispensable for cooperation with Stat5,
whereas the AF1 transactivation domain is required, thus suggesting that the GR acts as a ligand-dependent coactivator of
Stat5. In contrast, the Stat5 transactivation domain is not required for GR cooperation (48).
Diverse cross-modulations occur between Stats and steroid
receptors. Stat5 also antagonizes transcription by mineralocorticoid, progesterone, and estrogen receptors. However, only
mineralocorticoid and progesterone receptors enhance Stat5mediated transcription, which is inhibited by the estrogen receptor and unaffected by the androgen receptor (49). In contrast to Stat5 antagonism on transactivation by steroid
receptors, interleukin-6-activated Stat3 acts as a GR transcriptional coactivator (55).
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FIG. 7. Schematic diagram of functional Stat1-VDR interactions. Nuclear accumulation of Stat1 and the VDR by IFN-␥ and 1,25D promotes
physical interaction between Stat1 and the DBD of the VDR. Stat1-VDR complex formation inhibits VDR-RXR binding to VDRE and Stat1
deactivation by tyrosine dephosphorylation, thus resulting in IFN-␥ antagonism on 1,25D-VDR transactivation and 1,25D cooperation on
Stat1-mediated transcription.
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(32). IFN-␥-induced Stat1-VDR antagonism on 1,25D action
on macrophages, which cause high levels of 1,25D, is, however,
unlikely to affect TH1 lymphocytes, the main type responsible
for inflammatory responses, because these cells lack the IFN-␥
receptor ␤ chain (41), mandatory for IFN-␥ action.
VDR-Stat1 synergy may further enhance immunomodulation by 1,25D on monocytes/macrophages. In fact, synergistic
effects of 1,25D and IFN-␥ were reported previously for the
induction of nonspecific esterase (51) and NADPH oxidase (its
regulated subunits) (40) genes, two processes directly associated with terminal macrophage differentiation and enhanced
antimicrobicidal and antiviral potential. Since both 1,25D and
IFN-␥ are activators of macrophage immune function, high
levels of 1,25D could exert autocrine effects in activated macrophages by synergizing with IFN-␥, the most potent macrophage-activating cytokine.
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